Advertisement
Advertisement
U.S. Markets close in 3 hrs 9 mins
Advertisement
Advertisement
Advertisement
Advertisement

Amarin Corporation plc (AMRN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.6600+0.0500 (+3.11%)
As of 12:50PM EDT. Market open.
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • S
    Sharbe
    Volume speaks volume........
  • a
    art
    This from stocktwits
    The quarterly 13f filings for institutional ownership as of 6/30 aren't due until next week, but a couple (of those with over a million shares) have already filed. Acadian opened a new position of 1.52 million shares and Van Eck increased their position by 78%, to 1.4 million shares.
  • a
    art
    Actually AMRN was initially issued an NME ( new molecular entity) and received 3 years exclusivity. They petitioned the FDA to grant them an NCE ( new chemical entity) for 5 years. The FDA argued for two years that the formulation was not new since it existed in Lovaza, Amarin argued that IPE was not just a new formulation but an entirely new moiety never an active ingredient in any approved drug.

    Now concerning MND-2119. It’s a new formulation of IPE that already exists in VASCEPA so when approved it will be granted NME and get 3 years exclusivity. BTW there are three existing US patents on the MND-2119 formulation.
  • J
    Joe
    Large buying came in at 2PM EST on Monday and Wednesday...same thing going to happen on Friday???
    Be nice if they didn't skip a day and it happens again today.
  • m
    maurice
    Well I guess Amarin is not dead afterall!! Cheers!!!
  • a
    art
    This from dgon on stocktwits
    With self-emulsifying MND-2119 (licensed by Amarin): "post-dose EPA concentrations and increases from baseline were higher than that of ANCHOR in both MND-2119 doses, and higher than the results of REDUCE-IT at 1 year for MND-2119 at the 4 g/day dose" and "there were no remarkable safety differences between MND-2119 and EPA-E, and MND-2119 was safe and well tolerated. Recently, there have been reports of association between n-3 PUFA and atrial fibrillation, but in this study, no atrial fibrillation was observed in all treatment groups."
    Bring on Vascepa-2 & goodbye generics!
    https://www.sciencedirect.com/science/article/abs/pii/S1933287422001817
  • M
    MAGA
    Do you think AMRN may come back to $1.90 by this Friday?
  • s
    sv
    Breaking-News: Amarin targets Crestor-Vascepa combo, Stockvadar-reports

    In the last quarterly, CEO KM openly disclosed Amarin is investigating one or two statin-Vascepa formulations to move forward. On 3 August, Amarin hosted its conference call. The following day 4 August the lead statin candidate was revealed in a patent filing METHODS OF TREATING MIXED DYSLIPIDEMIA
    United States Patent Application 20220241234. The timing was perfect.

    Rosuvastatin or Crestor (brand name) by AstraZeneca

    What's interesting is how Amarin is approaching the 4 each Vascepa per day; only 1 capsule available in different strengths will contain Crestor, so it will probably be blister-packaged. "The method of claim 12, wherein the statin is rosuvastatin and 5 mg of the rosuvastatin is present in at least one of the four capsules." (5, 10, 20, 40 mg Crestor).

    Look up the patent and you'll see Amarin is being public about where it's likely heading in the clinic.

    -sv (long)
    Bullish
  • m
    maurice
    Another good day, a medication that works, when I see medications that are in trial and their stocks go up with no guarantees. Yeah I'll wait.
  • N
    Niall
    I will not post here again until this hits double figures. So it’s goodbye from me….
  • t
    tripsdad97
    Maybe Denner is buying and will file a 13D/A to start the proxy contest.
  • s
    sv
    Wallstreet leak: ReduceIt revealed highest effectiveness, Stockvadar-reports

    In the Vascepa- Crestor arm as data pool highlights. Amarin sitting on a second blockbuster.

    The technology floats Crestor pill in 1 of 4 blister pack Vascepa in four Crestor doses

    -sv (long)
    Bullish
  • S
    Sharbe
    The chart. Now above the 50 day moving average. There's a gap on the chart that needs to be filled at $2.69. Chart really looking good now.
  • I
    Israelweed
    The science always wins in the end. Follow the science
  • E
    Ed
    Sumthin's a brewin in Dublin, and it ain't Guiness
  • R
    Robert
    Accumulation
  • V
    VotingDem SurgesCrime
    If you've held this long or are a below $2 buyer then you might as well hold and hope for a Denner flip, a combo pull success, or a winning lawsuit that makes generics pay up big. Those are your 3 routes to a double or more from here.

    Your downside is that none of those happen and generics continue to erode the business and the EU sales continue to grow too slowly for any excitement or profitability and it stays below $2 or even moves into penny territory.

    Best of luck to you
  • j
    j
    I saw several big blocks cross in a 15-minute period:

    14:40:49 $ 1.405 297,200
    14:42:43 $ 1.405 455,600
    14:39:58 $ 1.405 169,600
    14:43:12 $ 1.405 544,400
    14:54:02 $ 1.425 420,000
    14:55:39 $ 1.435 420,000
    14:56:16 $ 1.435 400,000
    14:55:57 $ 1.435 500,000
  • l
    lazyr
    Something is happening today unbeknownst to the average investor since in late trading volume is doubled and up over 12% (8/8/22).
  • m
    maurice
    The company is expanding in Europe, sales in US seem to have bottomed, court case with insurance company on infringment, plenty of cash, account receivable and inventory. If I was to say that in 18 months with in excess of 500 m in sales in Europe, this stock triples from here, would you say that was a good investment. The answer is yes. If you're here to triple in the next week, you're dreaming. Cheers!!
Advertisement
Advertisement